T1	Participants 67 86	patients with GERD:
T2	Participants 172 225	patients with gastroesophageal reflux disease (GERD).
T3	Participants 475 610	adults with GERD-associated sleep disturbances and moderate-to-severe nighttime heartburn (recorded by patient diary during screening).
T4	Participants 611 723	Patients received oral esomeprazole 40 mg (n = 220) or 20 mg (n = 226) or placebo (n = 229) once daily for 4 wk.
